Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Secarna Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Secarna Pharmaceuticals Enters into Cooperation with Guangzhou’s Sun Yat-sen University to Develop a Treatment for SARS-CoV-2

              Contact the Supplier

              Lead Product(s): Antisense oligonucleotides

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sun Yat-sen University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 28, 2020

              Details:

              Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

              Ethris

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19

              Contact the Supplier

              Lead Product(s): NI007

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Neurimmune

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 01, 2020

              Details:

              Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.

              PharmaCompass__DigitalAd